Irene Ganan-Gomez

Aug 21, 2024 | digitalcommons.library.tmc.edu | Juan José Rodríguez-Sevilla |Irene Ganan-Gomez |Feiyang Ma |Kelly S. Chien

The molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetoclax after an initial response remain to be elucidated.

Aug 21, 2024 | digitalcommons.library.tmc.edu | Ziyi Li |Yizhuo Wang |Irene Ganan-Gomez |Simona Colla

MOTIVATION: Single-cell RNA sequencing (scRNA-seq) has been widely used to decompose complex tissues into functionally distinct cell types. The first and usually the most important step of scRNA-seq data analysis is to accurately annotate the cell labels. In recent years, many supervised annotation methods have been developed and shown to be more convenient and accurate than unsupervised cell clustering.

Feb 7, 2024 | nature.com | Feiyang Ma |Natalia Baran |Jintan Liu |Ken Furudate |Paola Storti |Irene Ganan-Gomez | +10 more

AbstractDNA damage resistance is a major barrier to effective DNA-damaging therapy in multiple myeloma (MM). To discover mechanisms through which MM cells overcome DNA damage, we investigate how MM cells become resistant to antisense oligonucleotide (ASO) therapy targeting Interleukin enhancer binding factor 2 (ILF2), a DNA damage regulator that is overexpressed in 70% of MM patients whose disease has progressed after standard therapies have failed.